Evidence map›Paper›PMID 41501122›Full record

ArticleScientific reports2026

The translation factor eIF4E is a key mediator of doxorubicin resistance: insights from a triple-negative breast cancer model.

Héctor Frayde-Gómez, Brenda Chimal-Vega, Angel Pulido-Capiz, Andrea Muñoz-Ayala, Octavio Galindo-Hernández, José Luis Vique-Sanchez, Ana Gabriela Leija-Montoya, Raúl Díaz-Molina, Pablo A Madero-Ayala, Marco A Ramos-Ibarra and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Héctor Frayde-GómezDepartamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali, California, 21000, México.
Brenda Chimal-VegaDepartamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali, California, 21000, México.
Angel Pulido-CapizDepartamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali, California, 21000, México.
Andrea Muñoz-AyalaDepartamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali, California, 21000, México.
Octavio Galindo-HernándezDepartamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali, California, 21000, México.
José Luis Vique-SanchezCentro de Innovación e Investigación en Salud, CIIS. Universidad Autónoma de Baja California, Mexicali, 21000, México.
Ana Gabriela Leija-MontoyaCentro de Innovación e Investigación en Salud, CIIS. Universidad Autónoma de Baja California, Mexicali, 21000, México.
Raúl Díaz-MolinaDepartamento de Educación e Investigación, Centro Cívico y Comercial, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar (IMSS-BIENESTAR), Av. Pioneros No. 1005, Palacio Federal, 3er piso, Mexicali, 21000, Baja California, México.
Pablo A Madero-AyalaGrupo de Investigación en Biotecnología y Biociencias, Facultad de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California, Tijuana, 22390, México.
Marco A Ramos-IbarraGrupo de Investigación en Biotecnología y Biociencias, Facultad de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California, Tijuana, 22390, México.
Victor García-GonzálezDepartamento de Bioquímica, Facultad de Medicina Mexicali, Universidad Autónoma de Baja California, Mexicali, California, 21000, México. vgarcia62@uabc.edu.mx.

Funding

23a. Convocatoria Interna de Apoyo a Proyectos de Investigación. Coordinación General de Investigación y Posgrado/UABC 2-12-213-2-003-2-1994Fondo Sectorial de Investigación para la Educación CB 2017-2018 1-S-28653/SEP/CONACYT
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) tumors are highly aggressive and typically associated with poor prognosis due to limited therapeutic options and significant chemoresistance. This study investigated the role of the translation initiation factor eIF4E in doxorubicin (Dox) resistance using a novel TNBC model. A doxorubicin-resistant cell variant, MDA

Indexed as

Antibiotics, AntineoplasticDoxorubicinDrug Resistance, NeoplasmEukaryotic Initiation Factor-4ETriple Negative Breast NeoplasmsATP Binding Cassette Transporter, Subfamily BCell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticHumansMatrix Metalloproteinase 9MDA-MB-231 CellsMolecular Docking SimulationPhosphorylationVascular Endothelial Growth Factor AABCB1 protein, humanAntibiotics, AntineoplasticATP Binding Cassette Transporter, Subfamily BDoxorubicinEIF4E protein, humanEukaryotic Initiation Factor-4EMatrix Metalloproteinase 9Vascular Endothelial Growth Factor AABCB1ChemoresistanceDoxorubicinEIF4ETriple-negative breast cancer

Identifiers

PMID41501122
PMCPMC12804909

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.